Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of BI 765080 in Healthy Men
NCT05075772Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2021
- Primary completion
- Mar 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of BI 765080 in chronic kidney disease (CKD) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of BI 765080 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point up to 1320 hours and Maximum Measured Concentration of BI 765080 in Plasma up to 1320 hours. Started Oct 2021; status: completed.
02
Drugs
BI 765080
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT05075772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05075772.